Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05470777 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL

StatusActive, Not Recruiting
PhasePhase 2
Started2020-01-19
View on ClinicalTrials.gov ↗
Chimeric antigen receptor T-cell (CAR-T) therapy has achieved remarkable efficacy in B-cell acute lymphoblastic leukemia (B-ALL). However, relapse after CAR-T has been a major issue. Multi-antigen CAR T and combination with other regimens may reduce the relapse rate. The investigators first conducted CD22/CD19 CAR T-cells and auto-HSCT "sandwich " strategy as consolidation therapy in patients with B-ALL. The main Purpose of this study was to observe the safety and efficacy of this new strategy.

Amendment history 1 change detected by DataLookout

2026-09-03
Primary completion pushed: 2026-07-21 → 2027-07-21
Trial Details
NCT Number NCT05470777
Lead Sponsor The First Affiliated Hospital of Soochow University
Collaborators: National Natural Science Foundation of China, Jiangsu Province Natural Science Foundation of China (Grant No. BK20210091), Jining Medical University, The Second People's Hospital of Huai'an, The First Affiliated Hospital of Bengbu Medical University, Northern Jiangsu People's Hospital, Affiliated Hospital of Nantong University, Suzhou Hospital of Traditional Chinese Medicine
Conditions B-cell Acute Lymphoblastic Leukemia
Enrollment 37 participants
Start Date 2020-01-19
Primary Completion 2027-07-21 (estimated)
Study Completion 2039-07-21 (estimated)
Updated on ClinicalTrials.gov 2026-09-02